Home
Search
BIO International Convention   |   June 16-19, 2025

Speakers & Presenters

All Speakers
By Count|Alphabetical
  • Show All
By Count|Alphabetical
  • Show All
By Count|Alphabetical
  • Show All
Company Type
  • Show All
Main Therapeutic Focus
  • Show All
Development Phase of Primary Product
  • Show All
Search Speakers
All Speakers
Filter by letter
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Results
Stephanie Marrus, MBA
MANAGING DIRECTOR, ENTREPRENEURSHIP, UNIVERSITY OF CALIFORNIA SAN FRANCISCO (UCSF)
Creative funding options for biotechs
Chris Marsh
CO-FOUNDER, LHON COLLECTIVE; MANAGING DIRECTOR, UBS
Precompetitive Collaborations in Rare Disease Research
San Diego, California, United States
Placeholder Photo
Matthew Martin
PRESIDENT, SAROS THERAPEUTICS
Saros Therapeutics
Placeholder Photo
Jewell Martin
ASSOCIATE DIRECTOR, US REGULATORY POLICY, BIOMARIN PHARMACEUTICAL, INC.
40 years of the Orphan Drug Act, the Rare Disease Endpoint Advancement (RDEA) Pilot Program, and Transforming Rare Disease Development
Tyler Martin
CHAIRMAN & CEO, AEOLIAN BIOTECH
Aeolian Biotech
Roca, Nebraska, United States
Petrina Martin Cherry
VICE PRESIDENT OF COMMUNITY ENGAGEMENT AND EXTERNAL AFFAIRS, BOSTON MEDICAL CENTER HEALTH SYSTEM
The Power of Community-Based Partnerships: Advancing Health Equity to Eliminate Disparities in Access to Care
Olivier Martinon, DVM, MS
VICE PRESIDENT, EXTERNAL INNOVATION & RESEARCH ALLIANCES, ZOETIS
Zoetis
Kalamazoo, Michigan, United States
Karen Martins
CHIEF, ANTIVIRALS AND ANTITOXINS, BARDA
New Tools in the Infectious Disease Toolbox: Combatting Future Biological Threats
Sabrina Martucci-Johnson
PRESIDENT & CHIEF EXECUTIVE OFFICER, DARE BIOSCIENCES OPERATIONS
Daré Bioscience
San Diego, California, United States
Stephen Mason
EXECUTIVE VICE PRESIDENT, REGULATORY POLICY, GREENLEAF HEALTH
FDA Sponsor Interaction: Best Practices and New PDUFA Formal Meetings